162:441451 Weiwer M, Bittker JA, Lewis TA, Shimada K, Yang WS, MacPherson L, Dandapani S, Palmer M, Stockwell BR, Schreiber SL et al (2012) Development of small-molecule probes that selectively kill cells induced to express mutant RAS
2026 is seeing exponential patient demand coupled with higher scrutiny from both the FDA and state boards of pharmacy, making it essential for 503A pharmacies to ensure strict compliance
Energy fades slowly
Secondary metabolites such as alkaloids, phenols, antibiotics, and others are highly crucial for defining the function and specificity of the diverse gut microbiome
As we move through 2026, the complexity of reimbursement models continues to grow
The inconsistencies in these studies reveal the need for further research with larger population groups